Importantly, JAK2-driven oncogenic signaling is amenable to pharmacologic inhibition with selective JAK inhibitors, such as ruxolitinib, underscoring a potential therapeutic avenue for this molecularly defined subset of ALL [11]. This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.